Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.41 |
| ▸ | TIPARP | Q7Z3E1 | 11/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23490301 | 0.99 | POLB (0.50) | POLBALDH1A1SMPD3TIPARPEPHX1 | |
| SCHEMBL23608681 | 0.99 | POLB (0.50) | POLBALDH1A1SMPD3TIPARPEPHX1 | |
| SCHEMBL23490504 | 0.93 | POLB (0.47) | POLBALDH1A1TIPARPTRPC5 | |
| SCHEMBL23490503 | 0.93 | POLB (0.47) | POLBALDH1A1TIPARPTRPC5 | |
| SCHEMBL23573422 | 0.90 | POLB (0.49) | POLBALDH1A1TIPARPEPHX1TRPC5 | |
| SCHEMBL23490296 | 0.90 | POLB (0.49) | POLBALDH1A1TIPARPEPHX1TRPC5 | |
| SCHEMBL23490295 | 0.90 | POLB (0.49) | POLBALDH1A1TIPARPEPHX1TRPC5 | |
| SCHEMBL23489983 | 0.89 | POLB (0.50) | POLBALDH1A1TIPARPEPHX1TRPC5 | |
| SCHEMBL23490463 | 0.89 | POLB (0.50) | POLBALDH1A1TIPARPEPHX1TRPC5 | |
| SCHEMBL23573176 | 0.89 | POLB (0.50) | POLBALDH1A1TIPARPEPHX1TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | PLEXXIKON INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021113625-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | POLB 1763/4885ALDH1A1 216/4885SMPD3 226/4885 |
| US-12509444-B2 | Compounds and methods for CD73 modulation and indications therefor | ENTPD5, ADORA1, ADORA2A | POLB 2540/4885ALDH1A1 114/4885SMPD3 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.